menu
    • menu
    [{"orgOrder":0,"company":"SciGen","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Zoledronic Acid","moa":"||Bone resorption","graph1":"Oncology","graph2":"Approved FDF","graph3":"SciGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SciGen \/ DKSH","highestDevelopmentStatusID":"15","companyTruncated":"SciGen \/ DKSH"},{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Zoledronic Acid","moa":"||Bone resorption","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"},{"orgOrder":0,"company":"Lene Bergendal Solberg","sponsor":"Vestre Viken Hospital Trust | F. Hoffmann-La Roche | Diakonhjemmet Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zoledronic Acid","moa":"||Farnesyl diphosphate synthase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Lene Bergendal Solberg","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Lene Bergendal Solberg \/ Vestre Viken Hospital Trust | F. Hoffmann-La Roche | Diakonhjemmet Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Lene Bergendal Solberg \/ Vestre Viken Hospital Trust | F. Hoffmann-La Roche | Diakonhjemmet Hospital"},{"orgOrder":0,"company":"IKF Nordwest","sponsor":"Recordati","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"||Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II","graph3":"IKF Nordwest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IKF Nordwest \/ Recordati","highestDevelopmentStatusID":"8","companyTruncated":"IKF Nordwest \/ Recordati"}]

    Find Clinical Drug Pipeline Developments & Deals for Reclast

    Menu

    Reclast

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Avenacy

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Avenacy

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zoledronic Acid,Inapplicable

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Avenacy Announces Launch of Zoledronic Acid Injection, USP in the U.S. Market

                            Details : Zometa-Generic (zoledronic acid) works by inhibition of bone resorption. It is indicated for the treatment of hypercalcemia of malignancy and for the treatment of multiple myeloma.

                            Product Name : Zometa-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 18, 2025

                            Lead Product(s) : Zoledronic Acid,Inapplicable

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SciGen

                            Singapore arrow
                            EPSC
                            Not Confirmed

                            SciGen

                            Singapore arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zoledronic Acid,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : DKSH

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            DKSH Has Successfully Entered into a Strategic Partnership with SciGen in Vietnam

                            Details : DKSH has enetered a strategic partnership with SciGen to supply Zometa (zoledronic acid) to the Vietnamese market. it is indicated for the treatment of Advanced cancers.

                            Product Name : Zometa

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 21, 2023

                            Lead Product(s) : Zoledronic Acid,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : DKSH

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            IKF Nordwest

                            Country arrow
                            EPSC
                            Not Confirmed

                            IKF Nordwest

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dinutuximab,Zoledronic Acid,Interleukin-2

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Recordati

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarco...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            October 18, 2021

                            Lead Product(s) : Dinutuximab,Zoledronic Acid,Interleukin-2

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Recordati

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lene Bergendal Solberg

                            Country arrow
                            EPSC
                            Not Confirmed

                            Lene Bergendal Solberg

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zoledronic Acid,Inapplicable

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase IV

                            Sponsor : Vestre Viken Hospital Trust | F. Hoffmann-La Roche | Diakonhjemmet Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zoledronate Early to Hip Fracture Patients - Safe and Effective?

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 27, 2021

                            Lead Product(s) : Zoledronic Acid,Inapplicable

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase IV

                            Sponsor : Vestre Viken Hospital Trust | F. Hoffmann-La Roche | Diakonhjemmet Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Massachusetts General Hospital

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Massachusetts General Hospital

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Denosumab,Zoledronic Acid

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase IV

                            Sponsor : University of California, San Francisco | San Francisco VA Health Care System

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            September 12, 2019

                            Lead Product(s) : Denosumab,Zoledronic Acid

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase IV

                            Sponsor : University of California, San Francisco | San Francisco VA Health Care System

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Columbia University

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Columbia University

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alendronate Sodium,Zoledronic Acid

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Amgen Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bisphosphonates for Prevention of Post-Denosumab Bone Loss

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 10, 2018

                            Lead Product(s) : Alendronate Sodium,Zoledronic Acid

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Amgen Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            CTTQ Pharma

                            Country arrow
                            EPSC
                            Not Confirmed

                            CTTQ Pharma

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zoledronic Acid,Calcium,Vitamin D

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Generic Zoledronic Acid Versus Original Zoledronic Acid in Postmenopausal Osteoporotic Women

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 18, 2017

                            Lead Product(s) : Zoledronic Acid,Calcium,Vitamin D

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ultragenyx Pharmaceutical

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            09

                            Aarhus University Hospital

                            Country arrow
                            EPSC
                            Not Confirmed

                            Aarhus University Hospital

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zoledronic Acid,Inapplicable

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase IV

                            Sponsor : University of Aarhus | Amgen Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 23, 2017

                            Lead Product(s) : Zoledronic Acid,Inapplicable

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase IV

                            Sponsor : University of Aarhus | Amgen Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Hamad Medical Corporation

                            Country arrow
                            EPSC
                            Not Confirmed

                            Hamad Medical Corporation

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Denosumab,Zoledronic Acid

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 02, 2017

                            Lead Product(s) : Denosumab,Zoledronic Acid

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth